📰 Jan Schellens News
Jan Schellens News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jan Schellens. Real-time updates on events, politics, business and more.
August 25, 2022
BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/ --
August 25, 2022
/PRNewswire/ -- Byondis B.V., an independent, clinical stage Dutch biopharmaceutical company creating precision medicines, today announced that the first...
July 12, 2022
/PRNewswire/ -- Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company creating precision medicines, announced today that the U.S. Food &...
July 12, 2022
FDA Accepts Byondis Biologics License Application for [Vic-] Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
July 12, 2022
The FDA has accepted the BLA for [vic-]trastuzumab duocarmazine to treat HER2-positive unresectable locally advanced or metastatic breast cancer.
June 10, 2021
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced or metastatic breast cancer (MBC).